Pharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an Update
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Bipolar disorder is a chronic, recurrent condition with the usual onset during adolescence or early adulthood. In the Diagnostic and Statistical Manual of Mental Disorders 5th edition, it is conceptualized as a spectrum disorder usually associated with such comorbidities as anxiety disorders and substance use disorders. It is a relatively prevalent condition often complicated by mixed episodes, rapid cycling, subsyndromal symptoms, and treatment refractoriness. In spite of carrying substantial morbidity and mortality, effective treatments are few and far between and conventional mood stabilizers are often unsuccessful in controlling the various manifestations of the disorder. In this scenario, second generation antipsychotics are emerging as treatments with valid efficacy in all phases of bipolar disorder. Quetiapine is a versatile atypical antipsychotic which was first approved for the treatment of schizophrenia, but latter on the basis of controlled studies earned United States Food and Drug Administration’s approval for acute as well as maintenance treatment of this difficult to treat condition. In this review, recently published studies in the last 10 years were examined to update the knowledge about the efficacy and safety of quetiapine in the treatment of bipolar disorder. The medication’s clinical pharmacology was first considered followed by a literature review summarizing its uses in bipolar disorder. The conclusion was that quetiapine was efficacious in manic, mixed and depressive episodes and as a maintenance agent with a good tolerability profile.
Abstract
Bipolar disorder is a chronic, recurrent condition with the usual onset during adolescence or early adulthood. In the Diagnostic and Statistical Manual of Mental Disorders 5th edition, it is conceptualized as a spectrum disorder usually associated with such comorbidities as anxiety disorders and substance use disorders. It is a relatively prevalent condition often complicated by mixed episodes, rapid cycling, subsyndromal symptoms, and treatment refractoriness. In spite of carrying substantial morbidity and mortality, effective treatments are few and far between and conventional mood stabilizers are often unsuccessful in controlling the various manifestations of the disorder. In this scenario, second generation antipsychotics are emerging as treatments with valid efficacy in all phases of bipolar disorder. Quetiapine is a versatile atypical antipsychotic which was first approved for the treatment of schizophrenia, but latter on the basis of controlled studies earned United States Food and Drug Administration’s approval for acute as well as maintenance treatment of this difficult to treat condition. In this review, recently published studies in the last 10 years were examined to update the knowledge about the efficacy and safety of quetiapine in the treatment of bipolar disorder. The medication’s clinical pharmacology was first considered followed by a literature review summarizing its uses in bipolar disorder. The conclusion was that quetiapine was efficacious in manic, mixed and depressive episodes and as a maintenance agent with a good tolerability profile.
참고문헌 (48)
- Kurumaji A., "Clinical course of the bipolar II disorder in a Japanese sample", J Affect Disord, 168, pp.363~366 (2014)
- Ghaemi SN., "The bipolar spectrum : conceptions and misconceptions", Aust N Z J Psychiatry, 48, pp.314~324 (2014)
- Whiteford HA., "Global burden of disease attributable to mental and substance use disorders : findings from the Global Burden of Disease Study 2010", Lancet, 382, pp.1575~1586 (2013)
- Clements C., "Suicide in bipolar disorder in a national English sample, 1996-2009 : frequency, trends and characteristics", Psychol Med, 43, pp.2593~2602 (2013)
- Fagiolini A., "Prevalence, chronicity, burden and borders of bipolar disorder", J Affect Disord, 148, pp.161~169 (2013)
- Vieta E., "Clinical management and burden of bipolar disorder : results from a multinational longitudinal study(WAVE-bd)", Int J Neuropsychopharmacol, 16, pp.1719~1732 (2013)
- Seeman P., "Atypical antipsychotics : mechanism of action", Can J Psychiatry, 47, pp.27~38 (2002)
- Maher AR., "Summary of the comparative effectiveness review on off-label use of atypical antipsychotics", J Manag Care Pharm, 18(5 Suppl B), pp.S1~S20 (2012)
- Hawkins SB., "Quetiapine for the treatment of delirium", J Hosp Med, 8, pp.215~220 (2013)
- Sanford M., "Quetiapine extended release : adjunctive treatment in major depressive disorder", CNS Drugs, 25, pp.803~813 (2011)
- Plosker GL., "Quetiapine : a pharmacoeconomic review of its use in bipolar disorder", Pharmacoeconomics, 30, pp.611~631 (2012)
- Bui K., "Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate(quetiapine XR) : clinical implications", Curr Med Res Opin, 29, pp.813~825 (2013)
- López-Muñoz F., "Active metabolites as antidepressant drugs : the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders", Front Psychiatry, 4, pp.102~ (2013)
- Altamura AC., "Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach : a prospective observational study", Clin Drug Investig, 32, pp.213~219 (2012)
- Kapur S., "A positron emission tomography study of quetiapine in schizophrenia : a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy", Arch Gen Psychiatry, 57, pp.553~559 (2000)
- Mundo E., "The use of atypical antipsychotics beyond psychoses : efficacy of quetiapine in bipolar disorder", Neuropsychiatr Dis Treat, 2, pp.139~148 (2006)
- Rasmussen H., "Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia", J Clin Psychopharmacol, 33, pp.266~269 (2013)
- Björkholm C., "Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine", Eur Neuropsychopharmacol, 23, pp.709~720 (2013)
- Silverstone PH., "Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects", Front Psychiatry, 3, pp.82~ (2012)
- Sümegi A., "Quetiapin in bipolar disorders", Neuropsychopharmacol Hung, 10, pp.281~291 (2008)
- Stahl SM., "Serotonergic drugs for depression and beyond", Curr Drug Targets, 14, pp.578~585 (2013)
- Hauge-Evans AC., "Effect of hyperglycaemia on muscarinic M3 receptor expression and secretory sensitivity to cholinergic receptor activation in islets", Diabetes Obes Metab, 16, pp.947~956 (2014)
- Locklear JC., "Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data", Clin Ther, 35, pp.1923~1932 (2013)
- Bortnick B., "Efficacy and tolerability of extended release quetiapine fumarate(quetiapine XR)monotherapy in major depressive disorder : a placebo-controlled, randomized study", J Affect Disord, 128, pp.83~94 (2011)
- Meltzer HY., "Update on typical and atypical antipsychotic drugs", Annu Rev Med, 64, pp.393~406 (2013)
- Gao K., "Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities : a randomized, placebo-controlled trial", J Clin Psychiatry, 75, pp.1062~1068 (2014)
- Singh J., "Antipsychotics in the treatment of bipolar disorder", Handb Exp Pharmacol, (212), pp.187~212 (2012)
- Sanford M., "Quetiapine : a review of its use in the management of bipolar depression", CNS Drugs, 26, pp.435~460 (2012)
- Yatham LN., "Atypical antipsychotics in bipolar depression : potential mechanisms of action", J Clin Psychiatry, 66(Suppl 5), pp.40~48 (2005)
- Myoung Suk Seo, "Potential Molecular and Cellular Mechanism of Psychotropic Drugs", Clinical Psychopharmacology and Neuroscience, 12(2), pp.94~110 (2014), 대한정신약물학회
- Malhi GS., "Optimal frequency of lithium administration in the treatment of bipolar disorder : clinical and dosing considerations", CNS Drugs, 25, pp.289~298 (2011)
- Woodward TC., "Cost effectiveness of adjunctive quetiapine fumarate extendedrelease tablets with mood stabilizers in the maintenance treatment of bipolar I disorder", Pharmacoeconomics, 28, pp.751~764 (2010)
- Sokolski KN., "Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.863~866 (2003)
- Pathak S., "Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial", J Clin Psychiatry, 74, pp.e100~e109 (2013)
- Vieta E., "Quetiapine monotherapy for mania associated with bipolar disorder : combined analysis of two international, doubleblind, randomised, placebo-controlled studies", Curr Med Res Opin, 21, pp.923~934 (2005)
- Buckley PF., "Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine", J Affect Disord, 100(Suppl 1), pp.S33~S43 (2007)
- Cutler AJ., "Extended-release quetiapine as monotherapy for the treatment of adults with acute mania : a randomized, double-blind, 3-week trial", Clin Ther, 33, pp.1643~1658 (2011)
- Ketter TA., "Acute and maintenance treatments for bipolar depression", J Clin Psychiatry, 75, pp.e10~ (2014)
- Lev-Ran S., "Bipolar disorder and co-occurring cannabis use disorders : characteristics, co-morbidities and clinical correlates", Psychiatry Res, 209, pp.459~465 (2013)
- Latalova K., "Suicide in bipolar disorder : a review", Psychiatr Danub, 26, pp.108~114 (2014)
- Young AH., "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression(EMBOLDEN I)", J Clin Psychiatry, 71, pp.150~162 (2010)
- McElroy SL., "A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression(EMBOLDEN II)", J Clin Psychiatry, 71, pp.163~174 (2010)
- Suppes T., "Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression", J Affect Disord, 121, pp.106~115 (2010)
- Suttajit S., "Quetiapine for acute bipolar depression : a systematic review and meta-analysis", Drug Des Devel Ther, 8, pp.827~838 (2014)
- Suppes T., "Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder : analysis of two large randomized, placebo-controlled trials", Depress Anxiety, 30, pp.1089~1098 (2013)
- Weisler RH., "Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder(Trial 144 : a randomized controlled study)", J Clin Psychiatry, 72, pp.1452~1464 (2011)
- Young AH., "A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder", World J Biol Psychiatry, 15, pp.96~112 (2014)
- Vieta E., "Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder", J Affect Disord, 142, pp.36~44 (2012)